SCHEMBL14366155

SCHEMBL14366155

CC[C@@H](O)COP(=O)(O)OC

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.43
LPAR5 Q9H1C0 2/20 0.39
PLA2G4A P47712 2/20 0.37
LPAR6 P43657 1/20 0.36
LPAR1 Q92633 1/20 0.36
LPAR4 Q99677 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36
LPAR3 Q9UBY5 1/20 0.36
ENPP2 Q13822 1/20 0.36
P2RY10 O00398 7/20 0.35
GPR174 Q9BXC1 6/20 0.35
GPR34 Q9UPC5 2/20 0.35
GPR55 Q9Y2T6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10301404 0.89 LPAR5 (0.42) LPAR5LPAR6LPAR1LPAR4LPAR2
SCHEMBL13112850 0.89 PLA2G2A (0.42) PLA2G2ALPAR5PLA2G4ALPAR6LPAR1
SCHEMBL6662556 0.83 SMN1; SMN2 (0.45) PLA2G2ALPAR5PLA2G4ALPAR6LPAR1
SCHEMBL14346966 0.83 SMN1; SMN2 (0.45) PLA2G2ALPAR5PLA2G4ALPAR6LPAR1
SCHEMBL14391572 0.83 LPAR5 (0.42) PLA2G2ALPAR5PLA2G4ALPAR6LPAR1
SCHEMBL18250368 0.83 LPAR5 (0.39) LPAR5LPAR6LPAR1LPAR4LPAR2
SCHEMBL12558548 0.80 LPAR5 (0.55) LPAR5LPAR6LPAR1LPAR4LPAR2
SCHEMBL14092736 0.80 P2RY10 (0.37) LPAR5LPAR6LPAR1LPAR4LPAR2
SCHEMBL21219391 0.79 LPAR5 (0.35) PLA2G2ALPAR5LPAR6LPAR1LPAR4
SCHEMBL15783767 0.79 PLA2G2A (0.43) PLA2G2APLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265216-A1 ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY WASHINGTON UNIVERSITY IN ST. LOUIS 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265216-A1 ENHANCED MEDICAL TREATMENT IN DIABETIC CARDIOMYOPATHY TNNI3, TNNT2, TNNC1 PLA2G2A 466/4885LPAR5 494/4885PLA2G4A 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.